How to get PT-141 (bremelanotide) legally, the real options

Last updated 2026-07-24

What is PT-141 and is it actually available legally?

PT-141 is the lab code name for bremelanotide, a peptide that the FDA approved in 2019 under the brand name Vyleesi for hypoactive sexual desire disorder (HSDD) in premenopausal women ^[1]. That approval is specific: it covers acquired, generalized low sexual desire that's causing distress, not low libido from a relationship problem, a medication side effect, or a medical condition that hasn't been addressed first ^[2]. So yes, it's legally available, but only as a prescription drug. There's no over-the-counter version and no legitimate generic yet. If you see "PT-141" sold as a bare vial with no prescription requirement, that's a research chemical listing, not the approved drug, and it's a different regulatory category entirely (more on that below). The approved product is self-administered as a subcutaneous injection using a single-dose auto-injector, given as needed at least 45 minutes before anticipated sexual activity ^{[3] [4]}. You can find the approval record directly in the FDA's own drug database if you want to verify this yourself .

How do you actually get a Vyleesi prescription?

You need a conversation with a licensed prescriber, in person or through telehealth, where HSDD gets discussed as a diagnosis, more than a symptom. Most clinicians will ask about duration of low desire, whether it's causing you personal distress, and what else might explain it (a new antidepressant, thyroid issue, menopause transition, or relationship stress can all mimic HSDD). After that conversation, if bremelanotide is judged appropriate, the prescriber sends it to a pharmacy. Vyleesi is dispensed through specialty and mail-order pharmacy channels more often than sitting on a shelf at your corner drugstore, so ask your provider which pharmacy they use, or whether they work with a specific fulfilling partner for it. This is also the point where you can ask practical questions: how many auto-injectors come in a package, how it's stored, and what to expect the first time you use it. A good pt-141-peptide-how-to-use guide covers injection technique in detail, but your pharmacist should walk you through it too when you pick it up.

Who is actually a candidate for PT-141?

The FDA approval is narrow on purpose: premenopausal women with acquired, generalized HSDD ^{[1] [5]}. Acquired means your desire used to be higher and dropped, generalized means it's not specific to one partner or situation. If your low desire has always been low, or it's tied to a specific relationship, Vyleesi's trial data doesn't really speak to your situation. The two phase 3 trials that led to approval, known as RECONNECT, enrolled women who met these criteria and measured change in desire and distress scores over 24 weeks ^[6]. A pre-specified subgroup analysis of that same program looked at whether age, menopausal status, or baseline severity changed the response, and found the effect held up across most subgroups, though the size of benefit was consistently modest ^[7]. Men sometimes ask about PT-141 for erectile difficulty. It's not FDA-approved for that use in men, and any product marketed that way is being sold off-label or as an unapproved research chemical. That's a meaningfully different risk picture than a monitored prescription.

What does PT-141 actually do in the brain (and why does that matter for how you get it)?

This is the detail most people skip past, but it explains a lot about why this drug is prescription-only and dosed the way it is. Bremelanotide is a melanocortin receptor agonist, meaning it acts on MC3R and MC4R receptors in the central nervous system, in brain regions tied to sexual motivation ^[8]. That's fundamentally different from sildenafil (Viagra) or similar drugs, which work on blood flow in the genital vasculature. PT-141 doesn't increase blood flow to produce its effect. It works upstream, in circuits that generate desire and arousal signals in the brain itself ^[8]. That central mechanism is also why side effects like nausea and flushing show up so often. The melanocortin system touches appetite and pigmentation pathways too, more than sexual desire alone ^[9]. This mechanism is part of why the melanocortin system is being studied well beyond sexual medicine. The same receptor family is a target in obesity and metabolic research, and one phase 1 dataset found measurable weight changes in obese women given bremelanotide, though that data comes from short trials not designed to establish it as a weight drug . None of that is a reason to seek it out for weight loss; it's just useful context for understanding what this receptor family does elsewhere in the body. If you want the deeper mechanism explanation, see pt-141 peptide.

How well does it actually work, based on the trial data?

Honestly, modestly. In the RECONNECT trials, women on bremelanotide had statistically significant improvement in desire scores and reduction in distress compared to placebo over 24 weeks ^[6]. But "statistically significant" and "life-changing" are not the same thing, and this is worth saying plainly rather than oversold. A 2024 reanalysis published in the Journal of Sex Research argued the effect sizes were small and questioned whether the clinical meaningfulness matched the regulatory bar that was applied ^[10]. A separate 2021 paper in the same journal, re-analyzing the phase 3 data, raised similar concerns about how responder thresholds were defined . A 2021 piece in Drug and Therapeutics Bulletin went further, comparing the bremelanotide and flibanserin approvals and arguing regulators applied a looser standard to these drugs than would be expected elsewhere ^[11]. None of this means the drug doesn't work for anyone. A phase 2b dose-ranging study found a meaningful share of women could be classified as "responders" at the 1.75 mg dose that eventually became the approved dose ^[12]. It does mean you should walk in with realistic expectations: this is a modest-effect drug for a specific diagnosis, not a guaranteed fix.

What's the actual dosing, and how is it different from sildenafil-type drugs?

Vyleesi comes as a 1.75 mg single-dose auto-injector, self-injected into the abdomen or thigh, taken as needed at least 45 minutes before anticipated sexual activity ^{[3] [4]}. It's not a daily pill. You use it on an as-needed basis, and the label caps use at one dose in 24 hours and no more than 8 doses per month ^[3]. That monthly cap matters and it's tied to the blood pressure response the drug can cause, which tends to be transient but is more pronounced with frequent dosing ^[9]. This is a real difference from as-needed erectile dysfunction drugs, which don't carry the same monthly dose ceiling. For the full breakdown of timing, injection sites, and what a typical dosing month looks like, the pt-141 dosage chart and pt-141 dosage calculator go through it step by step.

What side effects should you actually expect?

Nausea is the big one. Across the clinical development program, a pooled safety analysis found nausea was the most commonly reported adverse event, affecting a substantial share of women on active drug, with flushing and headache also common ^[13]. Nausea tends to be worse with the first couple of doses and often lessens with repeated use, though it doesn't disappear for everyone. Flushing (a warm, reddened feeling in the face and chest) is the second most common complaint ^{[13] [4]}. Some women also notice injection site reactions, headache, or a temporary rise in blood pressure that resolves within about 12 hours ^[9]. Because of that transient blood pressure effect, the label advises against using it more than the recommended monthly maximum, and it's generally avoided in women with uncontrolled high blood pressure or known cardiovascular disease . A less common but notable effect: some women notice temporary darkening of the skin, particularly on the face and gums, related to the melanocortin system's role in pigmentation. It's usually described as reversible with less frequent use, but you should mention it to your prescriber if you notice it. For the complete side effect breakdown by frequency, see pt-141 peptide side effects.

Why do so many websites sell PT-141 without a prescription, and is that safe?

Because bremelanotide is a peptide, it's easy to synthesize and sell as a "research chemical" without going through FDA drug approval, as long as it's labeled "not for human use." That labeling is a legal fig leaf; plenty of buyers use it anyway. Here's the regulatory reality: bremelanotide is not on the FDA's 503A bulk drug substances list for compounding pharmacies, nor on the 503B list for outsourcing facilities . Those lists determine which substances licensed compounding pharmacies can legally use to make patient-specific prescriptions. If a substance isn't on either list, a compounding pharmacy generally can't lawfully use it that way, and FDA maintains a separate list of substances nominated for compounding that have been considered and not added . That means gray-market PT-141 vials aren't coming from a regulated compounding supply chain at all. They're unregulated for purity, dose accuracy, and sterility. You have no way to verify what's actually in the vial, what concentration it is, or whether it was manufactured under any quality standard. Combine that with self-injection and a drug that affects blood pressure, and the risk profile is meaningfully worse than a prescribed, FDA-approved product with a known 1.75 mg dose per injector ^[3]. For more on why the Amazon and research-chemical listings you'll find online aren't the approved drug, see pt-141 peptide for sale amazon.

Can you get PT-141 through telehealth, and what does that visit look like?

Yes, and for a lot of women this is the realistic path, especially if you don't have a gynecologist or primary care provider who's comfortable discussing HSDD in detail. A telehealth visit for Vyleesi typically involves a structured intake about your sexual history, duration and pattern of low desire, current medications, and cardiovascular history (given the blood pressure effect) ^[9] . Expect questions that map onto the diagnostic criteria used in the trials: is the low desire new (acquired) rather than lifelong, is it present across situations (generalized) rather than partner-specific, and is it causing you distress rather than just being noticed by someone else ^[5]. A 2021 review in the Journal of Midwifery & Women's Health lays out this assessment process in more clinical detail if you want to read the diagnostic framework directly ^[5]. If bremelanotide seems appropriate, the prescription is then routed to a pharmacy for fulfillment. Bremelanotide Rx works from a provider-reviewed model exactly for this reason: the drug is genuinely useful for the right patient, but it needs a real clinical conversation first, not a checkout cart.

What alternatives exist if PT-141 isn't right for you?

Flibanserin (Addyi) is the other FDA-approved option for HSDD in premenopausal women, but it's a daily pill rather than an as-needed injection, and it carries its own restrictions around alcohol use ^[11]. Some clinicians will discuss both and let the dosing pattern (daily vs. as-needed) drive the choice. Beyond medication, a 2022 review in Current Psychiatry Reports on pharmacotherapy for sexual dysfunction in women points out that HSDD often has overlapping contributors, hormonal, psychological, relational, and treatment sometimes needs to address more than one at once ^[14]. A 2022 review in Current Opinion in Obstetrics & Gynecology makes a similar point: pharmacologic options work best as part of a broader plan that also considers relationship counseling or addressing an underlying medical cause ^[2]. If you're on antihypertensive medication or have a history of cardiovascular disease, a 2022 paper in Medicina specifically examines how blood pressure management interacts with female sexual dysfunction treatment, which is worth a read before starting bremelanotide .

Frequently asked questions

Is PT-141 the same thing as Vyleesi?

Yes. PT-141 is the research name for the compound bremelanotide, and Vyleesi is the FDA-approved brand name product containing it ^[1]. If you're buying something called "PT-141" that isn't labeled Vyleesi and doesn't require a prescription, it's not the same regulated product, even if the underlying molecule is chemically similar.

Do you need a prescription for PT-141?

For the FDA-approved product, yes, a prescription is required, and it's dispensed as Vyleesi through a pharmacy ^[1][4]. Vials sold online as "research use only" don't require a prescription, but they also aren't reviewed for purity, dose accuracy, or safety, which is a real gap, not a minor technicality.

Can men use PT-141?

Bremelanotide's FDA approval covers only premenopausal women with acquired, generalized HSDD ^[1]. It's not approved for men, and any marketing of PT-141 for male erectile difficulty is off-label or unapproved use. Men considering it should know it's working on a different mechanism entirely than approved ED drugs like sildenafil ^[20].

How is PT-141 different from Viagra or Addyi?

Bremelanotide works centrally, activating melanocortin receptors in the brain tied to sexual motivation ^[20]. Sildenafil works on genital blood vessels. Flibanserin (Addyi) is a daily pill affecting serotonin and dopamine pathways, taken every day rather than as-needed ^[17]. All three treat different problems and work through different systems.

What are the most common PT-141 side effects?

Nausea and flushing are by far the most common, reported across the pooled clinical development program as the leading adverse events ^[5][8]. Headache and injection site reactions are also reported. Some women notice a transient rise in blood pressure lasting up to about 12 hours after a dose ^[7].

How often can you use PT-141?

The Vyleesi label limits use to one dose in any 24-hour period, with a maximum of 8 doses per month, tied to its transient blood pressure effect ^[4]. It's not meant for daily or unlimited use, which is a meaningful difference from how some erectile dysfunction medications are dosed.

Does PT-141 actually work well?

The phase 3 RECONNECT trials showed statistically significant improvement in desire and reduced distress versus placebo ^[11], but multiple independent reanalyses have argued the effect size is modest and questioned whether it clears a meaningful clinical bar ^[21][24]. It works for some women; it's not a dramatic fix for most.

Who is not a good candidate for PT-141?

Women whose low desire isn't 'acquired and generalized' (meaning lifelong low desire, or desire that's partner-specific) aren't well matched to the trial evidence ^[3]. Uncontrolled high blood pressure or significant cardiovascular disease is also a concern given the drug's transient blood pressure effect ^[7][23].

Can you buy PT-141 without a doctor visit?

Unregulated vials are sold online without a prescription, but they're not the FDA-approved product and aren't on FDA's compounding bulk substance lists for legitimate pharmacy use ^[27][28]. There's no way to verify their purity or dosing, and using an unverified injectable that affects blood pressure carries real risk.

Is PT-141 available as a pill or only an injection?

The approved Vyleesi product is a subcutaneous auto-injector, not a pill ^[4]. Other delivery routes have been explored in early research, but nothing beyond the auto-injector is an approved consumer option right now.

Does PT-141 cause weight loss?

It's not approved or intended for weight loss. A phase 1 dataset in obese women found measurable body weight changes on bremelanotide, tied to the same melanocortin receptors involved in appetite regulation ^[26], but this was short-term trial data, not evidence it works as a weight-loss treatment.

How long does a single PT-141 dose take to work and last?

The label instructs use at least 45 minutes before anticipated sexual activity ^[4][8]. Individual response timing varies, and the drug isn't meant to be used more than once daily. Ask your prescriber about your specific timing based on the auto-injector instructions included with your prescription.

Sources

1. PubMed, Bremelanotide: First Approval (Drugs, 2019): FDA approved bremelanotide as Vyleesi in 2019 for hypoactive sexual desire disorder in premenopausal women
2. PubMed, Bremelanotide and flibanserin: the fallacy of regulatory precedent (Drug and Therapeutics Bulletin, 2021): the approval is specific to acquired, generalized HSDD causing distress, not general low libido
3. PubMed, Hypoactive Sexual Desire Disorder in Women: Physiology, Assessment, Diagnosis, and Treatment (Journal of Midwifery & Women's Health, 2021): diagnostic criteria for HSDD require desire loss to be acquired, generalized, and distressing
4. PubMed, Bremelanotide: New Drug Approved for Treating HSDD (The Annals of Pharmacotherapy, 2020): Vyleesi is a 1.75 mg subcutaneous auto-injector dosed as needed, capped at one dose per 24 hours and 8 doses per month
5. PubMed, Safety Profile of Bremelanotide Across the Clinical Development Program (Journal of Women's Health, 2022): nausea and flushing are the most commonly reported adverse events across the pooled clinical program
6. PubMed, The neurobiology of bremelanotide for HSDD in premenopausal women (CNS Spectrums, 2022): bremelanotide causes a transient rise in blood pressure resolving within about 12 hours, tied to dosing frequency
7. PubMed, Bremelanotide (Vyleesi) for hypoactive sexual desire disorder (The Medical Letter, 2019): the drug is used at least 45 minutes before anticipated sexual activity and flushing is a common adverse effect
8. PubMed, Pharmacotherapy for Sexual Dysfunction in Women (Current Psychiatry Reports, 2022): HSDD often has overlapping hormonal, psychological, and relational contributors requiring broader treatment planning
9. PubMed, Bremelanotide for the Treatment of HSDD: Two Randomized Phase 3 Trials (Obstetrics and Gynecology, 2019): the RECONNECT phase 3 trials showed statistically significant improvement in desire and reduced distress over 24 weeks versus placebo
10. PubMed, Pharmacologic therapeutic options for sexual dysfunction (Current Opinion in Obstetrics & Gynecology, 2022): pharmacologic treatment for HSDD works best combined with broader care addressing relationship or medical factors
11. PubMed, Prespecified and Integrated Subgroup Analyses from RECONNECT (Journal of Women's Health, 2022): subgroup analysis of RECONNECT trial data found treatment effect held across most subgroups with modest benefit size
12. PubMed, Small Effects, Questionable Outcomes: Bremelanotide for HSDD (Journal of Sex Research, 2024): a reanalysis argues bremelanotide's clinical trial effect sizes are small and questions the meaningfulness of the regulatory approval bar
13. PubMed, Responder Analyses from a Phase 2b Dose-Ranging Study of Bremelanotide (The Journal of Sexual Medicine, 2019): phase 2b dose-ranging data identified a meaningful share of responders at the 1.75 mg dose later approved
14. PubMed, Management of Hypertension with Female Sexual Dysfunction (Medicina, 2022): blood pressure management is a specific consideration when treating female sexual dysfunction with agents like bremelanotide
15. PubMed, Re-Analyzing Phase III Bremelanotide Trials for HSDD (Journal of Sex Research, 2021): a reanalysis of phase 3 data raised concerns about how responder thresholds were defined in the trials
16. PubMed, Effect of bremelanotide on body weight of obese women (Diabetes, Obesity and Metabolism, 2022): phase 1 data in obese women found measurable body weight changes with bremelanotide tied to melanocortin receptor activity
17. FDA, Bulk Drug Substances Used in Compounding Under Section 503A (21 CFR 216.23): bremelanotide is not on the FDA 503A list of bulk substances approved for compounding pharmacy use
18. FDA, 503B Bulks List (21 CFR 216.24): bremelanotide is not on the FDA 503B list of bulk substances approved for outsourcing facility compounding
19. FDA, Bulk Drug Substances Nominated for Use in Compounding (current list): FDA maintains a list of nominated substances considered for compounding use, separate from the approved 503A/503B lists
20. Drugs@FDA, FDA-Approved Drug Products Database: Vyleesi's FDA approval record can be verified directly in the agency's public drug database